Relation
Human recombinant soluble ACE2 (APN01) as a potential treatment for COVID-19
- the novel compounds under development is human recombinant soluble ACE2 (hrsACE2 [APN01; Apeiron Biologics, Vienna, Austria])
- 2 benefits:
- binding the viral spike protein and thereby neutralising SARS-CoV-2.
- minimising injury to multiple organs, including the lungs, kidneys, and heart, because of unabated renin–angiotensin system hyperactivation and increased angiotensin II concentrations
- hrsACE2 can reduce SARS-CoV-2 load by a factor of 1000–5000 in in-vitro cell-culture experiments
- hrsACE2 has been tested in 89 patients. After the first injection of hrsACE2 we observed a marked reduction of angiotensin II. Concurrent with reduced angiotensin II concentrations we detected a marked reduction in the inflammatory cytokine interleukin (IL)-6 and chemokine IL-8, both of which play an important role in lung injury and cytokine storm.
- hrsACE2 can reduce the cytokine storm which is the killer for COVID-19 patients
0
1
Updated 2020-09-29
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences